Clinical Trials Sponsored by Regimmune Inc.

Total 35964 results

MedImmune LLC

Completed

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

DERMATOMYOSITIS OR POLYMYOSITIS

United States
MedImmune LLC

Completed

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma (MEDI-546)

Scleroderma

United States
MedImmune LLC

Completed

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age (MI-CP185)

Healthy or Stable Underlying Chronic Medical Condition

United States
MedImmune LLC

Completed

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

Healthy

United States
MedImmune LLC

Terminated

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors (MEDI-547)

Cancer

United States
MedImmune LLC

Completed

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children (LAIV)

Healthy or Stable Chronic Illness

United States
MedImmune LLC

Completed

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

-Unhealthy Children With a History of Prematurity

United States
MedImmune LLC

Completed

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Leukemia

United States
MedImmune LLC

Completed

An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants

Apnea | Pneumonia | Bronchiolitis | Respiratory Infections

United States
MedImmune LLC

Completed

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Kidney Diseases

United States
MedImmune LLC

Completed

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Graft-Versus-Host Disease

United States
MedImmune LLC

Completed

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

Influenza

United States
MedImmune LLC

Completed

Long-Term Follow-Up Study of Psoriasis Patients

Psoriasis

Canada, United States, Belgium, France, Germany, Netherlands
MedImmune LLC

Withdrawn

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia
MedImmune LLC

Completed

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

Respiratory Syncytial Virus Infections

Chile, Argentina
MedImmune LLC

Completed

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Influenza

United States
MedImmune LLC

Completed

Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

Influenza
MedImmune LLC

Completed

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Influenza

United States
MedImmune LLC

Completed

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

Lupus

United States, Canada
MedImmune LLC

Completed

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Influenza

United States
MedImmune LLC

Completed

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Healthy

United States
MedImmune LLC

Completed

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

Rheumatoid Arthritis

United States, Canada
MedImmune LLC

Completed

Study to Evaluate MEDI-534 in Healthy Adults

Respiratory Syncytial Virus Infections | Parainfluenza Infections

United States
MedImmune LLC

Terminated

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Lymphoproliferative Disorders

United States
MedImmune LLC

Completed

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Healthy | Influenza

United States
Revimmune
Amarex Clinical Research

Terminated

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)

COVID-19 | Lymphocytopenia

United Kingdom
Epimmune
Pharmexa A/S; Pharmexa-Epimmune

Unknown

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) (EP1090)

HIV Infections

United States
Enimmune Corporation

Enrolling by invitation

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

Enterovirus Infections

Taiwan, Vietnam
Enimmune Corporation

Completed

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

Enterovirus Infections

Taiwan
Enimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

Enterovirus Infections

Taiwan
GlaxoSmithKline
MedImmune LLC

Completed

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Neoplasms

United States, Canada, Australia
Amgen
MedImmune LLC

Terminated

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

GI Adenocarcinoma

Germany, Netherlands
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
MedImmune LLC
Amgen

Completed

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

Asthma

United States, Slovakia, Israel, South Africa, Ukraine, Japan, Czechia, Hungary, Bulgaria, Serbia, Latvia, Lithuania
MedImmune LLC
Amgen

Completed

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (ALLEVIAD)

Atopic Dermatitis

United States, Germany, New Zealand, Hungary, Australia, Canada
AstraZeneca
MedImmune LLC

Completed

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Blood Cancer | Advanced B Cell Malignancies

Japan
AstraZeneca
MedImmune LLC

Completed

D2212C00002 J-Phase II Study

Idiopathic Pulmonary Fibrosis

Japan
MedImmune LLC
GlaxoSmithKline

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Cancer

United States
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

United States
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
MedImmune LLC
AstraZeneca

Suspended

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

Influenza Vaccine Effectiveness

United States, United Kingdom
MedImmune LLC
AstraZeneca

Completed

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Japan
AstraZeneca
MedImmune Ltd

Completed

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn's Disease

United States, France, Italy, Poland, Germany, Spain, Canada, Hungary, Czechia
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
MedImmune LLC
Amgen

Completed

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

United States, Sweden, France, United Kingdom
AstraZeneca
MedImmune LLC

Completed

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

Japan
AstraZeneca
MedImmune LLC

Completed

A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

Japan
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States

3

Subscribe